GE HealthCare Reveals Signa Sprint MRI Scanner

GE HealthCare has revealed Signa Sprint, a U.S. Food and Drug Administration (FDA) 510(k)-pending wide-bore 1.5T high-performance gradient MRI system.

The company said Signa Sprint was designed to unlock advanced imaging potential in cardiology, oncology, and other clinical and research areas. Its stated goal is to deliver higher gradient benefits previously possible only on 3T systems.

The new MRI’s 1.5T scanning boasts diffusion imaging, a key tool for oncology diagnosis and treatment planning. It also gives clinicians the ability to expand current 1.5T boundaries to enable fast clinical translation and pioneering research.

Signa Sprint’s high-gradient performance is 65/200 per axis. It’s designed for clear visualization of sub-millimetric structures and deep learning solutions to support oncology diagnostics abd treatment response monitoring.

The new system supports clinicians’ transition into quantitative MRI and a better understanding of tissue characteristics. Using deep-learning reconstruction for accelerated cardiac MRI hopes to reduce time and expertise needed to interpret scans, as well as drive consistency and reliability.

The MRI is also engineered for patient comfort with a 70-cm-wide bore space, free-breathing capabilities, and blanket-like AIR Coils.

“We are driven to push the boundaries of what’s possible in MRI with our ultra-premium segment, as our goal is to set a new standard in diagnostic research and precision care that allows for earlier clinical detection and treatment response,” said Kelly Londy, CEO, MR, GE HealthCare. “We are working to enhance diagnostic capabilities to provide highly accurate imaging with peace of mind for patients. We hope to help clinicians unlock new horizons for research in advanced imaging.”

Last week, the company earned an FDA nod for its Aurora nuclear medicine system and Clarify DL.